Meeting
2020 Genitourinary Cancers Symposium
Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).
Authors
Hamid Emamekhoo
University of Wisconsin Carbone Cancer Center, Madison, WI
Hamid Emamekhoo , Christos Kyriakopoulos , Glenn Liu , Douglas G. McNeel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03600350
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS273)
Abstract #
TPS273
Poster Bd #
P17
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.
First Author: Glenn Liu
Poster
2011 ASCO Annual Meeting
Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T and androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy.
First Author: E. S. Antonarakis
Poster
2024 ASCO Genitourinary Cancers Symposium
Mature results of a phase 2 pilot study of radium-223 and radiotherapy in untreated hormone-naïve men with oligometastatic prostate cancer to bone.
First Author: Jonathan David Tward
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz